ERA 2025 - Findings from a meta-analysis of chronic kidney disease outcomes in patients treated with empagliflozin suggest that people with CKD benefit from the drug irrespective of diabetes of albuminuria status. 

Prof    William Herrington (University of Oxford, Oxford, UK) joins us to discuss outcomes from an individual patient-level data meta-analysis, investigating the impact of diabetes, albuminuria, acute eGFR dip and disease severity on the effects of empagliflozin on the progression of CKD.

Findings showed that the treatment effect of empagliflozin was slightly larger in those with diabetes than those without, and larger in patients with low levels of albuminuria compared to those with high levels. 

Interview Questions:

1. What is the reasoning behind this subanalysis?
2. What were the key findings of this subanalysis, and were there any surprising or unexpected results?
3. What are the take-home messages?
4. Are there specific patient populations who might benefit from additional research on this topic?
5. What are the implications for current guidelines that recommend SGLT2 inhibitors across the spectrum of CKD?

Recorded on-site at ERA in Vienna, 2025.

Editors: Jordan Rance, Yazmin Sadik
Videographers: Tom Green, Dan Brent, David Ben Harosh

Support: This is an independent interview produced by Radcliffe CVRM.